about
Using the TAP component of the antigen-processing machinery as a molecular adjuvantIn vitro and in vivo studies for assessing the immune response and protection-inducing ability conferred by Fasciola hepatica-derived synthetic peptides containing B- and T-cell epitopesIntranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protectionImmunogenicity of a multi-component recombinant human acrosomal protein vaccine in female Macaca fascicularis.Preexposure of murine macrophages to CpG oligonucleotide results in a biphasic tumor necrosis factor alpha response to subsequent lipopolysaccharide challenge.Stability of a trivalent recombinant protein vaccine formulation against botulinum neurotoxin during storage in aqueous solutionCombined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity.Recombinant Hemagglutinin and Virus-Like Particle Vaccines for H7N9 Influenza VirusMF59™ as a vaccine adjuvant: a review of safety and immunogenicity.Molecular aspects of microparticle phagocytosis by dendritic cells.Evaluation of chemical degradation of a trivalent recombinant protein vaccine against botulinum neurotoxin by LysC peptide mapping and MALDI-TOF mass spectrometry.Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonistsInduction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.Calcium phosphate nanoparticle adjuvant.Orally administered Giardia duodenalis extracts enhance an antigen-specific antibody response.Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosisSpecific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infectionHMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen.Immunization with chaperone-peptide complex induces low-avidity cytotoxic T lymphocytes providing transient protection against herpes simplex virus infectionMimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivoCell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund's adjuvant, and monophosphoryl lipid AGM-CSF and IL-2 as adjuvant enhance the immune effect of protein vaccine against foot-and-mouth disease.Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection.Exploiting dendritic cells to improve vaccine efficacy.A Mast Cell Degranulation Screening Assay for the Identification of Novel Mast Cell Activating AgentsToward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in miceReview of L-tyrosine confirming its safe human use as an adjuvant.Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.Immunostimulant patch containing heat-labile enterotoxin from Escherichia coli enhances immune responses to injected influenza virus vaccine through activation of skin dendritic cells.Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenzaImmunoblot analysis of proteins associated with self-assembled monolayer surfaces of defined chemistries.Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickensSurvey of human-use adjuvants.Transcutaneous immunization and immunostimulant strategies: capitalizing on the immunocompetence of the skin.Exoerythrocytic malaria vaccine development: understanding host-parasite immunobiology underscores strategic success.Contemporary approaches to designing and evaluating vaccines against Chlamydia.Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
P2860
Q25256237-7928D485-8B3E-4566-B61A-195BA829B467Q28541967-D7EB8B56-BA93-4DB9-B962-0E2370DA7BDAQ28744570-EBFF4BC5-19D4-458F-96F6-798332EE1F12Q29394992-AD9B7E52-A32C-4019-BA7D-40EBF4DE8BD1Q30307037-E6002427-C8E4-49C7-95F4-53871C3D8DA9Q30371202-847C2973-B6F1-4966-AB55-C7DF04BC6266Q30374900-DD71F929-7D52-47BD-85FE-2E93F41027D3Q30380945-BAB2F309-3546-4E52-B6F5-F4604588CE44Q30394545-E038A2E8-2B9B-4E68-A8F5-C3517B81163DQ33259552-C3799E9C-953B-4B5F-B4DD-6C24DC7290C3Q33368131-E095AF59-015A-4E4A-9C03-AE36201F8647Q33721641-CF4A88E5-8317-4288-908D-5415FC01885AQ33845229-EA10B982-7D26-40A9-8C70-64232C38529CQ33944566-AD485C18-89CF-4DC9-BAF3-FF6E2076F87BQ33998717-53B29702-4326-4F91-BF57-D086EAD306CBQ34009465-89CE3D90-2DD5-4E40-95B8-A4251A83A8E1Q34122078-62F9A99F-770A-46D8-B5BB-FF4FEE9104BAQ34183386-2F8AD2FC-A770-485A-BF43-D8C1E3A9EAB1Q34194709-92D9A1E7-9FED-4CFA-8C8A-B805E235D6D2Q34238526-20BB2202-650B-424E-980B-DA5D214CC0AEQ34326744-82678894-EB21-4D41-BC08-9A69D7E419A7Q34348477-2608FCCE-1D3A-4C96-A823-C3BCD64694E8Q34351055-D3603131-FC04-4449-96E2-6BF1660A0D5CQ34510446-DC33DB04-549C-4E37-AD70-17574E1DF2AAQ34576055-AF9075A4-9D25-4E64-AA92-676F19DC18EAQ34681015-11DE6923-4828-47A3-902E-B57ECC8F6B81Q34691785-73944589-5E45-4AF3-9BB7-6CF568EB1A14Q34718609-A7D21093-F001-40BA-A528-64C1FA3FDDE5Q34719681-2A0CA304-98FD-4115-913B-06F250DFDE49Q34923189-24278EB5-5B41-4421-B8AE-AF61B8395724Q34932489-51E2C93C-8DE9-47EF-960D-85A8BB200EF5Q34976150-E65FBF5B-A4C2-467E-B182-C1D3A2AD7C8EQ35023393-2D2E7A0F-B0D1-430A-870E-8A1C050113E9Q35163420-486B33D7-0A44-4753-9C87-AC6B92DE29F6Q35191166-E6180E7B-5F2E-49F9-84E5-498089D7D5A9Q35192171-50817B06-0547-4C59-ABC9-5309363571CFQ35192195-694DD822-8BBB-4AF0-9BC0-2AA752278F23Q35193463-4B312DE8-76AC-465E-84F5-C9C7F6AAAF46Q35193566-388AD8C5-6362-4236-8762-0171B89C8DB4Q35209148-B46CF614-9401-49D4-9BF2-755767041E7A
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Advances in vaccine adjuvants.
@ast
Advances in vaccine adjuvants.
@en
type
label
Advances in vaccine adjuvants.
@ast
Advances in vaccine adjuvants.
@en
prefLabel
Advances in vaccine adjuvants.
@ast
Advances in vaccine adjuvants.
@en
P356
P1433
P1476
Advances in vaccine adjuvants.
@en
P2093
P2888
P304
P356
10.1038/15058
P577
1999-11-01T00:00:00Z